---
schema_version: "secwatch.filing_event.v1"
accession: "0001607678-25-000003"
form_type: "8-K"
ticker: "VKTX"
cik: "0001607678"
company_name: "Viking Therapeutics, Inc."
filed_at: "2025-08-19T23:59:59+00:00"
generated_at: "2026-05-17T11:27:39.211939+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# VK2735 oral tablet achieves up to 12.2% weight loss in Phase 2 obesity trial

## Summary
- Mean weight loss up to 12.2% (26.6 lbs) from baseline at 13 weeks; placebo-adjusted up to 10.9% (p<0.0001).
- Up to 97% of VK2735 subjects achieved ≥5% weight loss vs 10% placebo; up to 80% achieved ≥10% vs 5% placebo.
- Safety: 99% of GI-related TEAEs mild/moderate; discontinuation due to AE in 20% VK2735 vs 13% placebo.
- Statistically significant weight loss seen in all doses >15 mg from Week 1 through Week 13.
- Exploratory maintenance arm: weight loss sustained after down-titration from 90 mg to 30 mg daily for 7 weeks.

## SEC filing metadata
- accession: 0001607678-25-000003
- form_type: 8-K
- ticker: VKTX
- cik: 0001607678
- company_name: Viking Therapeutics, Inc.
- filed_at: 2025-08-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1607678/000160767825000003/0001607678-25-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1607678/000160767825000003/vktx-20250819.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001607678-25-000003
- JSON: https://secwatch.observer/filing/0001607678-25-000003.json
- Plain text: https://secwatch.observer/filing/0001607678-25-000003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.